Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Efficacy of HZV in Patients with IBD

Clin Gastroenterol Hepatol; ePub 2018 Oct 13; Khan, et al

Among veterans with inflammatory bowel diseases (IBD), vaccination was associated with a significantly reduced risk of herpes zoster infection but was underused in this population, a recent study found. Researchers conducted a retrospective cohort study using data from the national Veterans Affairs Healthcare System (VAHS) from January 1, 2000 through June 30, 2016. Data was collected from 39,983 veterans with IBD who had not received the HVZ by age 60 years. The follow-up period started at age 60 or the date of first IBD medication prescription and ended with the earliest diagnosis of HZ infection, the end of the study period, or date of death. Among the findings:

  • 7,170 patients (17.9% of total cohort, 96.6% male and 94.2% Caucasian) who received the HZV during the follow-up period were identified.
  • The crude incidence rate of HZ infection during the follow-up period for unvaccinated patients was 6.97/1,000 person-years and for vaccinated patients was 4.09/1,000 person-years.
  • Vaccination was associated with significantly lower risk of HZ infection vs lack of vaccination (adjusted hazard ratio, 0.54).

Citation:

Khan N, Trivedi C, Kavani H, Medvedeva E, Lewis J, Yang YX. Efficacy of live attenuated herpes zoster vaccine in patients with inflammatory bowel diseases. [Published online ahead of print October 13, 2018]. Clin Gastroenterol Hepatol. doi:10.1016/j.cgh.2018.10.016.